Prostatic acid phosphatase inhib 
Welcome,         Profile    Billing    Logout  
 1 Company  1 Product   1 Product   0 Diseases   3 Trials   35 News 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Provenge (sipuleucel-T) / Bausch Health
ProvONE, NCT06134232: Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

Not yet recruiting
3
400
NA
Sipuleucel-T Injection
Dendreon
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
12/31
06/32
ProVent, NCT03686683: Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer

Completed
3
532
US
sipuleucel-T
Dendreon, PRA Health Sciences
Adenocarcinoma of the Prostate
03/23
03/23
NCT05751941: Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

Recruiting
2
26
US
Abiraterone, Enzalutamide, Xtandi, Apalutamide, Sipuleucel-T, Provenge
H. Lee Moffitt Cancer Center and Research Institute, Dendreon
Prostate Cancer, Metastatic Prostate Cancer
03/25
12/25
NCT06100705: Sipuleucel-T Combined with Bipolar Androgen Therapy in Men with MCRPC

Recruiting
2
26
US
Testosterone Cypionate, DEPO-Testosterone, Sipuleucel-T, Provenge
Yale University, Dendreon
Metastatic Castration-resistant Prostate Cancer
12/27
03/28
OU-SCC-EXCITE, NCT05806814: Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer

Recruiting
1
13
US
Sipuleucel-T, PROVENGE
University of Oklahoma, Dendreon
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
06/26
12/26
MVI-816 / Madison Vaccines
NCI-2018-01474, NCT03600350: pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer

Active, not recruiting
2
19
US
pTVG-HP, Nivolumab, Opdivo, GM-CSF, Leukine, Sargramostim
University of Wisconsin, Madison, Bristol-Myers Squibb, Madison Vaccines Inc. (MVI), AIQ Solutions
Prostate Cancer
12/22
12/27
NCI-2019-07273, NCT04090528: pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Active, not recruiting
2
60
US
pTVG-HP, pTVG-AR, Pembrolizumab, Keytruda
University of Wisconsin, Madison, Merck Sharp & Dohme LLC, Madison Vaccines Incorporated, Prostate Cancer Foundation
Castration-resistant Prostate Cancer, Metastatic Cancer, Prostate Cancer
11/24
10/26
NCT02499835: Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer

Completed
1/2
66
US
Pembrolizumab, 1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1), Lambrolizumab, Keytruda, MK-3475, SCH 900475, pTVG-HP Plasmid DNA Vaccine
University of Wisconsin, Madison, Prostate Cancer Foundation, Madison Vaccines, Inc
Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
08/21
07/23
HB-300 / Hookipa Pharma
NCT05553639: HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer

Terminated
1/2
12
US
HB-302/HB-301 Alternating 2-Vector Therapy
Hookipa Biotech GmbH
Prostate Cancer Metastatic
04/24
04/24
VTP-850 / Barinthus Bio
NCT05617040: Prime-boost Immunotherapeutic Trial in Men with Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Terminated
1/2
22
US
ChAdOx1-PCAQ, MVA-PCAQ
Barinthus Biotherapeutics
Prostate Cancer
02/25
02/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Provenge (sipuleucel-T) / Bausch Health
ProvONE, NCT06134232: Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

Not yet recruiting
3
400
NA
Sipuleucel-T Injection
Dendreon
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
12/31
06/32
ProVent, NCT03686683: Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer

Completed
3
532
US
sipuleucel-T
Dendreon, PRA Health Sciences
Adenocarcinoma of the Prostate
03/23
03/23
NCT05751941: Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

Recruiting
2
26
US
Abiraterone, Enzalutamide, Xtandi, Apalutamide, Sipuleucel-T, Provenge
H. Lee Moffitt Cancer Center and Research Institute, Dendreon
Prostate Cancer, Metastatic Prostate Cancer
03/25
12/25
NCT06100705: Sipuleucel-T Combined with Bipolar Androgen Therapy in Men with MCRPC

Recruiting
2
26
US
Testosterone Cypionate, DEPO-Testosterone, Sipuleucel-T, Provenge
Yale University, Dendreon
Metastatic Castration-resistant Prostate Cancer
12/27
03/28
OU-SCC-EXCITE, NCT05806814: Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer

Recruiting
1
13
US
Sipuleucel-T, PROVENGE
University of Oklahoma, Dendreon
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
06/26
12/26
MVI-816 / Madison Vaccines
NCI-2018-01474, NCT03600350: pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer

Active, not recruiting
2
19
US
pTVG-HP, Nivolumab, Opdivo, GM-CSF, Leukine, Sargramostim
University of Wisconsin, Madison, Bristol-Myers Squibb, Madison Vaccines Inc. (MVI), AIQ Solutions
Prostate Cancer
12/22
12/27
NCI-2019-07273, NCT04090528: pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Active, not recruiting
2
60
US
pTVG-HP, pTVG-AR, Pembrolizumab, Keytruda
University of Wisconsin, Madison, Merck Sharp & Dohme LLC, Madison Vaccines Incorporated, Prostate Cancer Foundation
Castration-resistant Prostate Cancer, Metastatic Cancer, Prostate Cancer
11/24
10/26
NCT02499835: Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer

Completed
1/2
66
US
Pembrolizumab, 1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1), Lambrolizumab, Keytruda, MK-3475, SCH 900475, pTVG-HP Plasmid DNA Vaccine
University of Wisconsin, Madison, Prostate Cancer Foundation, Madison Vaccines, Inc
Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
08/21
07/23
HB-300 / Hookipa Pharma
NCT05553639: HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer

Terminated
1/2
12
US
HB-302/HB-301 Alternating 2-Vector Therapy
Hookipa Biotech GmbH
Prostate Cancer Metastatic
04/24
04/24
VTP-850 / Barinthus Bio
NCT05617040: Prime-boost Immunotherapeutic Trial in Men with Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Terminated
1/2
22
US
ChAdOx1-PCAQ, MVA-PCAQ
Barinthus Biotherapeutics
Prostate Cancer
02/25
02/25

Download Options